logo
Flies disguised as wasps can't fool birds

Flies disguised as wasps can't fool birds

Yahoo02-07-2025
Despite their bee-like appearance, hoverflies are all buzz, no bite. The harmless insects, more closely related to midges than wasps, imitate their distant stinging cousins with stripes, high contrast colors, and narrow waists. In theory, the 'flies in wasps' clothing' use this strategy to ward off would-be predators, without having to pay the cost of evolving venom and an appendage to inject it. But in practice, it's an open question how well the tactic works.
The quality of hoverfly mimicry can vary– from detailed disguises to the insect equivalent of slapping on a pair of cat ears for a Halloween party. Evolutionary biologists have long questioned why it is that some hoverflies bother with such inaccurate impersonations, and why poor mimicry persists in populations.
New research offers a possible explanation. Even questionable copycats can trip up certain predators like spiders and praying mantises, according to a study published July 2 in the journal Nature. In contrast, other predators are tougher to trick. Using unconventional methods, the researchers showed just how good birds are at distinguishing wasp mimics from the real sting, and what particular traits make the difference.
The team created intricate, 3D printed models of hypothetical insect chimeras to explore the whole range from 100 percent wasp to fully fly. Across four experiments with wild birds, domestic chicks, and invertebrates, they observed how different potential predators responded to a variety of artificial mimics.
It's 'a novel way to ask questions that have been discussed in the literature a lot, but not very rigorously tested,' Tom Sherratt, an evolutionary ecologist at Carleton University in Ottawa, tells Popular Science. Sherratt wasn't involved in the study, but co-wrote an accompanying News & Views piece about the research. 'I thought it was a really nice paper,' he says, 'they had a great idea for these 3D printed insects.'
Most prior research of mimicry uses real insect specimens or crude stimuli, like colored squares, to examine predator response. But those approaches come with limitations. Either the cue is rudimentary and it's difficult to evaluate outcomes, or 'you're restricted to only what's in nature,' Christopher Taylor, lead study author and an evolutionary biologist at the University of Nottingham in England, tells Popular Science. In contrast, 3D printing opened up an entire world of possibilities. Taylor and his colleagues were able to finely tune each of the models used across their experiments with the desired mix of features, and better assess the importance of some changes over others.
They found that great tits (Parus major), a common species of European songbird, have a hyper discerning eye. After a short period of training, the wild birds were able to pick out most of the fake wasps. They could also readily discern between the 'jack of all trade' mimics that mix traits from different targets and models of actual, stinging insects. Taylor and his many co-authors further found that color and size were the most critical aspects of successful mimics, over shape and pattern, in trials with recently hatched domestic chickens. Finally, they discovered that crab spiders and praying mantises are much more easily put off by inaccurate wasp mimics than birds, offering an explanation for why evolution has guided some flies to invest in half measures.
'In some situations, but not all, [poor mimics] persist because they can get away with it. They don't need to be super accurate in all respects in order to fool a predator–with the caveat that it depends on what their main predators are,' explains Taylor.
In other words: If your main threats are other insects or spiders, appearing unappetizing and potentially dangerous is a lower lift. If you're particularly tasty to birds, you'll probably have to try harder.
[ Related: Scientists discover how some flowers mimic the smell of death. ]
To reach that conclusion, the scientists began by conducting 3D scans of real wasps and flies, and then using those digitized insects to construct fake ones. They printed plastic versions of the real insects, fly/wasp hybrid variants ranging from 25 to 75 percent similarity, hybrids between two different species of real wasps, and versions of the wasp/fly chimeras where color, size, shape, or pattern were the focus of the hypothetical mimicry.
In their first experiment, the scientists presented wild great tits with puzzle grids made up of small lidded dishes. On top of each was one of their 3D insect models. Beneath the fly or fly hybrids, the researchers placed a tasty mealworm. Nothing was placed in the wasp containers.. Over weeks of observation, they recorded what order the birds approached containers in. After a short period of teaching the tits that flies advertised a treat while wasps advertised wasted time, the birds readily separated even convincing fly mimics from wasps. The birds significantly favored the fly and fly hybrid boxes over the wasp boxes, according to the findings.
The team also verified that what the birds learned from the figurines would apply to the real thing by running a trial where some of the plastic critters were swapped with pinned, dead insects. They found that the birds associated the real flies with food and the real wasps with less likelihood of reward.
In another experiment, they conducted similar trials, but with 3D models of two different species of wasp and hybrids spanning the gap between both. They found that the birds were easily able to tell the difference between the insect models, and readily learned that the plastic replicas of the true wasps had no food to offer, while the hybrid 'mimics' were worth foraging for.
Then, Taylor and co presented baby chickens with different versions of hypothetical wasp mimics, to tease out which traits were the most important for keeping predators at bay. After food reward training, they timed how long it took for the chicks' to attack or examine the insect models. When the insect models were yellow and black or accurately sized to match a common wasp, the birds delayed pecking for longer. Wasp-like patterns and shapes, on the other hand, were less of a deterrent.
In their invertebrate trials, the team placed jumping spiders, crab spiders, and praying mantises in an arena with a series of 3D printed insects, one at a time, spanning from full fly to true wasp. In the presence of the plastic wasps, the researchers administered a 'punishment' to most of the test subjects by prodding them in the abdomen. With and without training, the mantises and crab spiders showed a significantly different response to the flies than to the wasps, and were much more cautious of lesser intermediate mimics than the birds had been. Jumping spiders, which have better vision than many other invertebrates, were better able to tell hybrids and true wasps apart.
On their own, each of these experiments 'would be good papers,' says Sherratt. 'But the fact that we've got all of them under one roof is what I think really helps make this paper quite interesting and imaginative.'
[ Related: This spider pretends to be an ant, but not well enough to avoid being eaten. ]
Though imaginative, 3D printing does come with limitations. For one, the plastic insect figurines are purely visual cues. They can't replicate the behavior, sound, or chemical aspects of an actual, living hoverfly or wasp, notes Taylor. It's quite possible these less printable features might be part of how predators pick their meals and learn to avoid unpleasant experiences. Then, there's the fact that the birds in the study were trained and tested on a reward/no reward basis. In nature, the risk of picking on a wasp isn't just that you might miss a meal, it's also that you could be hurt, says Sherratt. Under those higher stakes conditions, birds in reality might be less willing to approach wasp mimics than they were in the experiments.
Still, the study is an 'ambitious' foray into a new frontier of biology research, Sherratt says. He imagines scientists using similar methods to explore sexual selection and other forms of mimicry.
Taylor hopes their approach for exploring imagined adaptations allows for clearer answers about why and when species settle into a long-term form.
'It feeds into this larger question about evolution,' he says. 'You see a broad range of adaptations in nature, but how well-adapted does a particular species need to be before it kind of reaches the peak?'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vaccines hold tantalizing promise in the fight against dementia
Vaccines hold tantalizing promise in the fight against dementia

Yahoo

timean hour ago

  • Yahoo

Vaccines hold tantalizing promise in the fight against dementia

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization estimates that vaccination prevents between 3 million and 5 million deaths annually from diseases like diphtheria, tetanus, influenza, measles and, more recently, COVID-19. While there has long been broad scientific consensus that vaccines prevent or mitigate the spread of infections, there is new research suggesting that the therapeutic impact might go beyond the benefit of preventing infectious diseases. An April 2025 study published in the prominent journal Nature found tantalizing evidence that the herpes zoster – or shingles – vaccine could lower the risk of dementia in the general population by as much as 20%. We are a team of physician scientists with expertise in the clinical and basic science of neurodegenerative disorders and dementia. We believe that this study potentially opens the door to other breakthroughs in understanding and treating dementia and other degenerative disorders of the brain. A role for vaccines in reducing dementia risk? One of the major challenges researchers face when trying to study the effects of vaccines is finding an unvaccinated 'control group' for comparison – a group that is similar to the vaccine group in all respects, save for the fact that they haven't received the active vaccine. That's because it's unethical to assign some patients to the control group and deprive them of vaccine protection against a disease such as shingles. The Nature study took advantage of a policy change in Wales that went into effect in 2013, stating that people born on or after September 2, 1933, were eligible for the herpes zoster vaccination for at least a year, while those born before that cutoff date were not. The vaccine was administered to prevent shingles, a painful condition caused by the same virus that causes chickenpox, which can lie dormant in the body and be reactivated later in life. The researchers used the policy change as a natural laboratory of sorts to study the effect of shingles vaccination on long-term health outcomes. In a statistically sophisticated analysis of health records, the team found that the vaccine reduced the probability of getting dementia by one-fifth over a seven-year period. This means that people who received the shingles vaccine were less likely to develop clinical dementia over the seven-year follow-up period, and women benefited more than men. The study design allowed researchers to compare two groups without actively depriving any one group of access to vaccination. The two groups were also of comparable age and had similar medical comorbidities – meaning similar rates of other medical conditions such as diabetes or high blood pressure. Results from this and other related studies raise the possibility that vaccines may have a broader role in experimental therapeutics outside the realm of infectious diseases. These studies also raise provocative questions about how vaccines work and how our immune system can potentially prevent dementia. How vaccines might be protective One scientific explanation for the reduction of dementia by the herpes zoster vaccine could be the direct protection against the shingles virus, which may play a role in exacerbating dementia. However, there is also the possibility that the vaccine may have conferred protection by activating the immune system and providing 'trained immunity,' in which the immune system is strengthened by repeated exposure to vaccines or viruses. The study did not differentiate between different types of dementia, such as dementia due to Alzheimer's disease or dementia due to stroke. Additionally, researchers cannot draw any definitive conclusions about possible mechanisms for how the vaccines could be protective from an analysis of health records alone. The next step would be a prospective, randomized, double-blind, placebo-controlled study – the 'gold standard' for clinical trials in medicine – to directly examine how the herpes zoster vaccine compares with a placebo in their ability to reduce the risk of dementia over time. Such studies are necessary before any vaccines, as well as other potential therapies, can be recommended for routine clinical use in the prevention of dementia. The challenges of untangling dementia Dementia is a major noncommunicable disease that is a leading cause of death around the world. A January 2025 study provided updated figures on lifetime dementia risk across different subsets of the U.S. population. The researchers estimate that the lifetime risk of dementia after age 55 is 42% – more than double earlier estimates. The dementia risk was 4% by age 75, and 20% by age 85, with the majority of risk occurring after 85. The researchers projected that the number of new cases of dementia in the U.S. would double over the next four decades from approximately 514,000 cases in 2020 to 1 million in 2060. Once considered a disease largely confined to the developed world, the deleterious effects of dementia are now apparent throughout the globe, as life expectancy increases in many formerly developing countries. While there are different forms of dementia with varying clinical manifestations and underlying neurobiology, Alzheimer's disease is the most common. Prospective studies that specifically test how giving a vaccine changes the risk for future dementia may benefit from studying patient populations with specific types of dementia because each version of dementia might require distinct treatments. Unfortunately, for the past two to three decades, the amyloid hypothesis of Alzheimer's disease – which posits that accumulation of a protein called amyloid in the brain contributes to the disorder – dominated the scientific conversation. As a result, most of the efforts in the experimental therapeutics of Alzheimer's disease have focused on drugs that lower the levels of amyloid in the brain. However, results to date have been modest and disappointing. The two recently approved amyloid-lowering therapies have only a minimal impact on slowing the decline, are expensive and have potentially serious side effects. And no drug currently approved by the Food and Drug Administration for clinical use reverses the cognitive decline. Studies based on health records suggest that past exposure to viruses increase the risk of dementia, while routine vaccines, including those against tetanus, diphtheria, pertussis, pneumonia, shingles and others, reduce the risk. Innovation and an open mind There is sometimes a tendency among scientists to cling to older, familiar models of disease and a reluctance to move in more unconventional directions. Yet the process of doing science has a way of teaching researchers like us humility, opening our minds to new information, learning from our mistakes and going where that data takes us in our quest for effective, lifesaving therapies. Vaccines may be one of those paths less traveled. It is an exciting possibility that may open the door to other breakthroughs in understanding and treating degenerative disorders of the brain. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Anand Kumar, University of Illinois Chicago and Jalees Rehman, University of Illinois Chicago Read more: Whooping cough is making a comeback, but the vaccine provides powerful protection Until a coronavirus vaccine is ready, pneumonia vaccines may reduce deaths from COVID-19 Monkeypox vaccines: A virologist answers 6 questions about how they work, who can get them and how well they prevent infection Jalees Rehman receives funding from NIH. Anand Kumar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment. Solve the daily Crossword

Severe AKI Tied to Reduced Survival in Patients on ECMO
Severe AKI Tied to Reduced Survival in Patients on ECMO

Medscape

time2 hours ago

  • Medscape

Severe AKI Tied to Reduced Survival in Patients on ECMO

TOPLINE: A notable proportion of patients receiving veno-venous extracorporeal membrane oxygenation (ECMO) for acute respiratory failure developed acute kidney injury (AKI), likely due to the greater severity of the underlying disease. Severe AKI was independently associated with reduced hospital survival, regardless of whether it occurred before or during ECMO. METHODOLOGY: Researchers conducted a retrospective cohort study to evaluate the prevalence, survival, and risk factors for AKI in 500 patients undergoing veno-venous ECMO for acute respiratory failure (median age, 55 years; 30% women). Patients were categorised into three groups: those with the onset of AKI before ECMO, those with its onset during ECMO, and those with its onset both before ECMO and a new onset of AKI during ECMO after an initial recovery. AKI was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Patients were followed up for survival up to 1 year after hospital discharge to assess long-term outcomes. Propensity score matching was performed between patients without AKI and those with its onset during ECMO to analyse risk factors. TAKEAWAY: Overall, 64% (n = 320) developed AKI, 182 of whom had the onset of the condition before ECMO and 158 during ECMO. The overall survival to hospital discharge was 67% (n = 335), with severe AKI (KDIGO stage 3) associated with reduced hospital survival regardless of its onset before or during ECMO (P = .001). Patients with the onset of AKI before veno-venous ECMO had significantly higher levels of inflammatory markers and required higher doses of norepinephrine at the initiation of ECMO than those without AKI, highlighting a greater severity of the underlying disease. Similarly, among patients who developed vs did not develop AKI during ECMO, markers of disease severity and sepsis such as high organ failure scores, high levels of C reactive protein, and low mean arterial pressure emerged as risk factors. IN PRACTICE: "AKI is a frequent complication in patients supported with VV [veno-venous]-ECMO. AKI onset before VV-ECMO-therapy is linked to the severity of the underlying disease. AKI onset during VV-ECMO is less due to ECMO-related factors but also to the severity of the disease and septic episodes," the authors wrote. SOURCE: This study was led by Franziska Fuchs and Clemens Wiest, University Hospital Regensburg in Regensburg, Germany. It was published online on August 01, 2025, in Kidney360. LIMITATIONS: The study's retrospective design limited its generalisability and the establishment of causal conclusions. Data on patients before hospital admission were limited. The prevalence of AKI may have been affected by using creatinine alone for diagnosis and the lack of baseline data on creatinine and urine output. DISCLOSURES: No funding information was provided for this study. Some authors declared being employees, board or committee members, advisors, or consultants of various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Research on reversing Alzheimer's reveals lithium as potential key
Research on reversing Alzheimer's reveals lithium as potential key

Yahoo

time3 hours ago

  • Yahoo

Research on reversing Alzheimer's reveals lithium as potential key

Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer's disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages. Researchers led by Bruce A. Yankner, a professor of genetics and neurology at Harvard Medical School, reported that they were able to reverse the disease in mice and restore brain function with small amounts of the compound lithium orotate, enough to mimic the metal's natural level in the brain. Their study appeared Wednesday in the journal Nature. Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. 'The obvious impact is that because lithium orotate is dirt cheap, hopefully we will get rigorous, randomized trials testing this very, very quickly,' said Matt Kaeberlein, former director of the Healthy Aging and Longevity Research Institute at the University of Washington, who did not participate in the study. 'And I would say that it will be an embarrassment to the Alzheimer's clinical community if that doesn't happen right away.' Yankner, who is also the co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard, said: 'I do not recommend that people take lithium at this point, because it has not been validated as a treatment in humans. We always have to be cautious because things can change as you go from mice to humans.' He added that the findings still need to be validated by other labs. Although there have been recent breakthroughs in the treatment of Alzheimer's, no medication has succeeded in stopping or reversing the disease that afflicts more than 7 million Americans, a number projected to reach almost 13 million by 2050, according to the Alzheimer's Association. Lithium is widely prescribed for patients with bipolar disorder, and previous research indicated that it held potential as an Alzheimer's treatment and an antiaging medication. A 2017 study in Denmark suggested the presence of lithium in drinking water might be associated with a lower incidence of dementia. However, the new work is the first to describe the specific roles that lithium plays in the brain, its influence on all of the brain's major cell types and the effect that its deficiency later in life has on aging. Results of the study by Yankner's lab and researchers at Boston Children's Hospital and the Rush Alzheimer's Disease Center in Chicago also suggest that measuring lithium levels might help doctors screen people for signs of Alzheimer's years before the first symptoms begin to appear. Yankner said doctors might be able to measure lithium levels in the cerebrospinal fluid or blood, or through brain imaging. - - - How our brains use lithium In a healthy brain, lithium maintains the connections and communication lines that allow neurons to talk with one another. The metal also helps form the myelin that coats and insulates the communication lines and helps microglial cells clear cellular debris that can impede brain function. 'In normal aging mice,' Yankner said, 'lithium promotes good memory function. In normal aging humans,' higher lithium levels also correspond to better memory function. The depletion of lithium in the brain plays a role in most of the deterioration in several mouse models of Alzheimer's disease. Loss of lithium accelerates the development of harmful clumps of the protein amyloid beta and tangles of the protein tau that resemble the structures found in people with Alzheimer's. Amyloid plaques and tau tangles disrupt communication between nerve cells. The plaques in turn undermine lithium by trapping it, weakening its ability to help the brain function. Lithium depletion is involved in other destructive processes of Alzheimer's: decay of brain synapses, damage to the myelin that protects nerve fibers and reduced capacity of microglial cells to break down amyloid plaques. Lithium's pervasive role comes despite the fact that our brains contain only a small amount of it. After examining more than 500 human brains from Rush and other brain banks, Yankner's team discovered the naturally occurring lithium in the brain is 1,000 times less than the lithium provided in medications to treat bipolar disorder. Li-Huei Tsai, director of the Picower Institute for Learning and Memory at Massachusetts Institute of Technology and who was not involved in the study, called it 'very exciting,' especially when many in the field, including her own lab, have focused on genetic risk factors for Alzheimer's. 'But clearly genetic risk factors are not the only things,' said Tsai, who is also Picower professor of neuroscience. 'There are a lot of people walking around carrying these risk genes, but they are not affected by Alzheimer's disease. I feel this study provides a very important piece of the puzzle.' - - - Pathways for treatment Alzheimer's treatments mostly help to manage symptoms and slow the decline it causes in thinking and functioning. Aducanumab, lecanemab, and donanemab, all lab-made antibodies, bind to the harmful amyloid plaques and help remove them. Donepezil, rivastigmine and galantamine ― all in the class of medications known as cholinesterase inhibitors ― work by replenishing a chemical messenger called acetylcholine, which is diminished in Alzheimer's. Acetylcholine plays an important role in memory, muscle movement and attention. Yankner and his team found that when they gave otherwise healthy mice a reduced-lithium diet, the mice lost brain synapses and began to lose memory. 'We found that when we administered lithium orotate to aging mice [that had] started losing their memory, the lithium orotate actually reverted their memory to the young adult, six month level,' he said. Lithium orotate helped the mice reduce production of the amyloid plaques and tau tangles, and allowed the microglial cells to remove the plaques much more effectively. Yankner said one factor that might help lithium orotate reach clinical trials sooner is the small amount of the treatment needed, which could greatly reduce the risk of harmful side effects, such as kidney dysfunction and thyroid toxicity. Aside from its potential in treating Alzheimer's, Yankner said lithium orotate might also have implications for the treatment of Parkinson's disease, an area his lab is investigating. 'That needs to be rigorously examined,' he said. 'But we're looking at a whole slew of disorders.' Related Content Trump is threatening to take over D.C. Here's what he can and can't do. They once shared recipes. Now her family is going hungry in Gaza. Pets are being abandoned, surrendered amid Trump's immigration crackdown Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store